MCRB vs. OCGN, AMRN, AARD, MDWD, TVGN, ANNX, FHTX, SLRN, DSGN, and URGN
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Ocugen (OCGN), Amarin (AMRN), Aardvark Therapeutics (AARD), MediWound (MDWD), Tevogen Bio (TVGN), Annexon (ANNX), Foghorn Therapeutics (FHTX), Acelyrin (SLRN), Design Therapeutics (DSGN), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.
Seres Therapeutics vs. Its Competitors
Seres Therapeutics (NASDAQ:MCRB) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.
In the previous week, Ocugen had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Ocugen and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 1.89 beat Ocugen's score of 1.04 indicating that Seres Therapeutics is being referred to more favorably in the media.
Seres Therapeutics has a beta of 2.62, meaning that its stock price is 162% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.2, meaning that its stock price is 320% more volatile than the S&P 500.
Ocugen has lower revenue, but higher earnings than Seres Therapeutics. Ocugen is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. Seres Therapeutics' return on equity of 0.00% beat Ocugen's return on equity.
Seres Therapeutics currently has a consensus target price of $73.67, indicating a potential upside of 821.99%. Ocugen has a consensus target price of $6.00, indicating a potential upside of 400.00%. Given Seres Therapeutics' higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Ocugen.
Seres Therapeutics received 416 more outperform votes than Ocugen when rated by MarketBeat users. However, 71.43% of users gave Ocugen an outperform vote while only 70.99% of users gave Seres Therapeutics an outperform vote.
59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by insiders. Comparatively, 4.4% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Seres Therapeutics and Ocugen tied by winning 9 of the 18 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MCRB) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy MCRB Stock Free MCRB Stock Alerts